共 568 条
[51]
Hasserjian R(2010)Chronic myeloid leukemia: mechanisms of blastic transformation J Clin Invest. 120 2254-4094
[52]
Thiele J(2010)Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1 Leukemia. 24 1128-447
[53]
Borowitz MJ(2010)Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations Blood. 116 4086-1664
[54]
Le Beau MM(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood. 129 424-2091
[55]
Papaemmanuil E(2011)Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia Leukemia. 25 1661-863
[56]
Gerstung M(2017)Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation Blood. 129 2083-754
[57]
Bullinger L(2004)Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha Immunity. 21 853-52659
[58]
Gaidzik VI(2015)Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia Jpn J Clin Oncol. 45 749-170
[59]
Paschka P(2003)Restoration of C/EBPalpha expression in a BCR-ABL+ cell line induces terminal granulocytic differentiation The Journal of biological chemistry. 278 52651-e206
[60]
Roberts ND(2011)Development of t(8;21) and RUNX1-RUNX1T1 in the Philadelphia-positive clone of a patient with chronic myelogenous leukemia: additional evidence for multiple steps involved in disease progression Cancer Genetics. 204 165-1291